INR Above or Below the Therapeutic Range
Increased INR, Coumadin over-dosage; low INR, inadequate Coumadin dosage
Clinical conditions that increase Coumadin effect and elevate INR include:
Low vitamin K intake
Poor nutritional state
Congestive heart failure
Connective tissue diseases
Conditions known to decrease Coumadin effect and decrease INR include:
High vitamin K intake
Many drugs are known to increase warfarin effect and elevate INR:
Effects may be dose-dependent & may not occur in all pts receiving Coumadin & the drug mentioned.
Drugs in this category include carbenicillin, allopurinol, erythromycin, indomethacin, ibuprofen, fluconazole, fenoprofen, isoniazid, ketoconazole, naproxen, metronidazole, phenylbutazone, moxalactam, cephalosporins, trimethoprim-sulfa (Bactrim), amiodarone, quinidine, cimetidine, clofibrate, lovastatin, omeprazole, phenytoin, tamoxifen, thyroxine, quinolones, rofecoxib, celecoxib.Drugs that can decrease warfarin effect & lower INR in some pts include antacids, antihistamines, barbiturates, rifampin, sucralfate, trazodone, carbamazepine, cholestyramine, griseofulvin, haloperidol, oral contraceptives, penicillin, dicloxacillin, and nafcillin.
Suggested Additional Lab Testing
Most important: INR value on a daily basis until patient shows a consistent value within therapeutic range at least 2 or 3 times.
Monitoring is then less frequent but at least 1 times per month.
Lab tests may be helpful in uncovering other conditions, such as liver disease, which lowers the level of coagulation factors and makes therapeutic anticoagulation difficult. Pharmacogenomics testing is a consideration, either before initiation of warfarin, shortly after initiation, or for patients with apparent hypersensitivity to warfarin.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
The Cardiology Advisor Articles
- AHA/ACC: Updated Management Guidelines for Adult Congenital Heart Disease
- Patient Connectivity Benefits Familial Chylomicronemia Syndrome
- Genetic Screening in Preventive Care: Advances and Challenges
- Vitamin D Independently, Inversely Tied to Cholesterol in Children
- Chronic Total Occlusions on CCTA Increase Major Adverse Cardiac Event Risk
- Apixaban Lowers Bleeding Risk in Afib With End-Stage Kidney Disease
- Tricuspid Regurgitation Velocity Unreliable Indicator of Pulmonary Hypertension
- Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes
- The Challenge of Compassion in Modern Healthcare Settings
- Concomitant NSAID and Anticoagulant Use May Increase Stroke, Bleeding Risk in Afib
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Relationship Between HbA1c and Coronary Artery Disease
- E-Cigarette Vapor Condensate Toxic to Alveolar Macrophages
- Death Risk Not Increased in T2DM When Risk Factors Within Target
- AHA Issues Scientific Statement on Managing Chagas Cardiomyopathy